INTRODUCTION
Obesity and the metabolic syndrome are major contributors to morbidity and mortality from a variety of diseases affecting virtually all organ systems (1) . Obesity is essentially a disorder of lipid accumulation, primarily in the form of triacylglycerols (TAGs) in adipose tissue. TAGs serve as a critical reservoir for lipid metabolites involved not only in energy homeostasis but also other essential cellular processes including membrane synthesis and cell signaling. In the context of chronic energy excess and/or impaired lipid metabolism, TAGs accumulate in metabolicallyrelevant non-adipose tissues such as liver where they are associated with cellular and systemic
METHODS

Generation of the Pnpla3 targeting construct and Pnpla3-KO mice.
The Pnpla3 targeting construct was generated using bacterial artificial chromosome (BAC) recombineering techniques (45, 46) . A BAC vector (pBACe3.6) containing Pnpla3 from the 129SvEV/AB2.2 mouse strain (BAC clone bMQ-381F07) was obtained from the Wellcome Trust Sanger Institute. Nucleotides from -12 to +1927 (1939 bp) of the Pnpla3 gene were replaced by a neomycin resistance cassette, The resulting targeting construct was electroporated into 129 embryonic stem (ES) cells followed by antibiotic selection under standard conditions. Antibioticresistant ES cell clones were screened by Southern blotting to identify clones with homologous recombination. Appropriately targeted ES cells were then injected into C57BL/6 blastocysts and implanted into pseudopregnant females with the assistance of the transgenic core facility at Beth Israel Deaconess Medical Center. Resulting chimeric mice were screened by PCR to identify mice with germline transmission of the targeted allele (WT allele: forward 5' ggggcggggtacgtggattagaga, reverse 5' agccctgcccacaaccccaaaag, 296 bp; targeted allele: forward 5' cggccgcttgggtggagag, reverse 5' caggtagccggatcaagcgtatgc, 358 bp). Mice carrying the targeted allele were then backcrossed to C57BL/6 mice for at least 4 generations (N4).
Animals.
For evaluation of adipose-and liver-specific Pnpla3 mRNA expression in response to highfat (HF) feeding and leptin-deficiency, tissues were collected from a) overnight-fasted 24 weekold male FVB mice (Taconic) fed chow diet (14 kcal% fat, Harlan Teklad RD8664) or HF diet (42 kcal% fat, Harlan Teklad TD88137) since weaning (47) , and b) ad lib-fed 10 week-old Lep ob weight following a 6h fast. For insulin tolerance tests (ITTs), mice were injected intraperitoneally with regular human insulin (HumulinR; Lilly) at 0.80 units per kg of body weight following a 4h fast. Serum corticosterone was determined by radioimmunoassay as described (47) . Other serum parameters were determined using the following kits: insulin (Ultra Sensitive Mouse Insulin ELISA Kit, Crystal Chem), TAG (Infinity Triglycerides Liquid Stable Reagent, Thermo Scientific), NEFA (HR Series NEFA-HR(2) Reagents, Wako Diagnostics), cholesterol (Cholesterol E, Wako Diagnostics), alanine aminotransferase (ALT/SGPT Test, Stanbio Laboratory), and aspartate aminotransferase (AST/SGOT Test, Stanbio Laboratory).
TAG hydrolase activity.
TAG hydrolase activity was determined as described (51). Briefly, tissues were homogenized in lysis buffer (0.25 M sucrose, 1 mM EDTA, 1 mM dithiothreitol, 20 μg/ml leupeptin, 2 μg/ml antipain, 1 μg/ml pepstatin, pH 7.0). Lysates were then centrifuged for 60 min at 100,000 x g at 4°C to isolate lipid-free infranatants. Triolein substrate containing [9,10-3H]triolein as radioactive tracer was prepared by sonication as described (52). Cytosolic fractions (0.1 ml) with or without 500 ng/assay of purified CGI-58 and/or 25μM of the HSLspecific inhibitor 76-0079 (NNC 0076-0000-0079, Novo Nordisk) were incubated with 0.1 ml (167 nmol) of substrate at 37°C for 60 min. Reactions were terminated by adding 3.25 ml of methanol/chloroform/heptane (10:9:7) and 1 ml of 0.1 M potassium carbonate, 0.1 M boric acid, at pH 10.5. After centrifugation at 800 x g for 20 min, the radioactivity in 1 ml of the upper phase was determined by liquid scintillation counting.
Ex vivo lipolysis in perigonadal white adipose tissue (WAT) explants.
Ex vivo tissue lipolysis was determined as described (53). Briefly, ~20 mg pieces of perigonadal WAT was incubated in DMEM (Invitrogen) containing 2% fatty acid-free BSA (Sigma) with or without 10 μM isoproterenol (Sigma) at 37°C. NEFA and glycerol release were determined in aliquots of incubation buffer collected at the times indicated using NEFA-HR (2) reagents (Wako Diagnostics) and Infinity Triglycerides Liquid Stable Reagent (Thermo Scientific), respectively. Results were normalized to tissue protein content as determined by the bicinchoninic acid method (Pierce).
Biochemical and histological determination of tissue TAG content.
For biochemical determination of liver TAG content, liver tissue (~20-30 mg) was ground in liquid nitrogen and extracted by the method of Folch (54). Dried lipid extracts were re-dissolved in 60 µL tert-butanol plus 40 µL of a 2:1 mixture of Triton X-114:methanol. TAG content was then determined using Infinity Triglycerides Liquid Stable Reagent (Thermo Scientific). Liver TAG content was confirmed histologically by Oil Red O staining using standard methods (55).
In vivo cholesterol and fatty acid synthesis.
In vivo rates of cholesterol and fatty acid synthesis were measured in mouse tissues using 3H-labeled water (ICN) as described (56). Mice were fasted for 2 h at the early phase of the light cycle and then injected intraperitoneally with [3H]-H 2 O (50 mCi in 0.25 ml isotonic saline).
One hour after the injection, mice were sacrificed, and liver, perigonadal WAT, and intrascapular brown adipose tissue (BAT) were collected. Lipids were extracted from tissues and 3H-labeled fatty acids and digitonin-precipitable sterols (DPSs) were determined as described (57, 58).
Rates of fatty acid and cholesterol synthesis were calculated as μmol 3H-radioactivity incorporated into fatty acids or DPSs per hour per gram of tissue, respectively.
Mass spectrometric analysis of lipids.
The quantitative analysis of TAG molecular species was performed as described (59, 60).
Briefly, lipids were extracted from mouse tissues using a modified method of Bligh and Dyer (61) in the presence of internal standards for electrospray ionization mass spectrometric 10 by guest, on November 9, 2017 www.jlr.org Downloaded from (ESIMS) analysis. ESIMS analyses were performed using a TSQ Quantum Ultra Plus triplequadrupole mass spectrometer (ThermoFisher Scientific) equipped with an automated nanospray apparatus (Nanomate HD, Advion Bioscience Ltd.) and Xcalibur system software.
RNA extraction, reverse transcription, and gene expression analysis.
Total RNA was extracted from homogenized tissues using RNeasy Lipid Tissue Mini Kit with on-column DNase treatment (Qiagen). Reverse transcription of 1 g total RNA was performed using random decamers (RETROscript Kit, Ambion, Inc.). Gene expression was determined by qPCR (7300 Real-time PCR System, ABI) using gene-specific primer-probe sets (Taqman Gene Expression Assays, Applied Biosystems) normalized to cyclophilin (forward 5'
agccgggacaagccactgaaggat) or 18S ribosomal RNA (Applied Biosystems) reference genes using the standard curve method as described (62) . Appropriate analysis was performed to determine that expression of reference genes were unchanged under the experimental conditions described. Accuracy of RNA quantification was optimized by DNase treatment of samples, use of gene-specific primer-probe sets that span intron-exon boundaries, and verification of lack of amplification in no-RT and no-template controls. Experimental parameters conformed to MIQE guidelines (63) .
RESULTS
Pnpla3 mRNA expression in adipose tissue and liver is altered in murine models of fatty liver and metabolic syndrome.
Pnpla3 mRNA expression is highly regulated by acute nutritional and hormonal challenges in both adipose tissue and liver (25, (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (29) . These data suggest that Pnpla3 may be regulated differently in leptin-deficient/resistant obesity compared to diet-induced obesity. However, similar to dietinduced obesity, Pnpla3 expression was substantially increased in liver (22-fold) in mice with leptin deficiency. Thus, Pnpla3 mRNA expression is altered in adipose tissue and liver of two common models of fatty liver and metabolic syndrome, thereby supporting a potential role for PNPLA3 in the pathogenesis and/or physiological adaptation to these disorders.
Mice with global targeted deletion of Pnpla3 lack Pnpla3 expression in metabolicallyrelevant tissues.
To better understand the physiological relevance of PNPLA3, including its contribution to fatty liver and metabolic syndrome, we generated a murine model with global targeted deletion of Pnpla3 (Pnpla3-KO mice) ( Fig. 2A-B Fig. 3C and 3D , respectively) or BAT (data not shown). These data suggest that PNPLA3 does not contribute significantly to TAG hydrolysis in murine tissues.
Global targeted deletion of Pnpla3 does not affect energy homeostasis.
Because PNPLA3 could have activities other than TAG hydrolysis that could influence metabolism, we performed comprehensive metabolic phenotyping of Pnpla3-KO and WT mice in response to chronic nutritional challenges known to induce Pnpla3 expression (i.e. highsucrose feeding and diet-induced obesity). Specifically, mice were fed a standard chow diet as well as three diets with identical protein content but differing in sucrose and fat content -a "control" low-fat low-sucrose diet (LFLS), a low-fat high-sucrose diet (LFHS), and a high-fat (data not shown). Likewise no differences were identified between genotypes for oxygen consumption, respiratory exchange ratios (RER), or physical activity in the ad lib-fed, fasted, or re-fed states (8 week-old males, n=4-6/group; data not shown). Thus, Pnpla3 deficiency does not alter overall energy homeostasis in response to chronic nutritional challenges.
Global deletion of Pnpla3 does not affect systemic glucose tolerance, insulin sensitivity, or serum lipid homeostasis.
To determine the effect of Pnpla3 deficiency on systemic lipid/glucose homeostasis and insulin action, we next evaluated body weight and serum parameters in response to acute nutritional challenges (ad lib feeding, fasting, re-feeding) in mice fed LFLS, LFHS, and HFHS diets from weaning until 12 weeks of age ( Table 1) . As expected, both diet and feeding status had significant main effects on body weight and serum parameters, consistent with the appropriate metabolic responses. Further analysis revealed significant interactions between diet and genotype for NEFA (NEFA were lower in KO than WT in LFHS-fed mice but trended higher in KO than WT in HFHS-fed mice) and between feeding status and genotype for cholesterol (cholesterol was higher in KO than WT in re-fed mice). However, no main effects were identified for genotype on body weight, glucose, insulin, TAGs, NEFAs, or cholesterol. Furthermore, no consistent or reproducible differences between genotypes were identified for these parameters in terminal blood from ad lib-fed 19 week-old mice from the above diet groups, in terminal blood from 11 week-old chow-fed mice fasted for intervals ranging from 4-16 hours, or in terminal blood from 8-10 week-old chow-fed mice fasted for 12h followed by 12h of re-feeding LFHS diet
(data not shown). Finally, both genotypes from the above diet groups had similar serum glucose responses to intraperitoneal glucose ( Fig. 5A-D) and insulin ( Fig. 5E-H ) challenges, indicating no differences in systemic glucose tolerance or insulin sensitivity, respectively. These data argue against a significant effect of genotype on these parameters, but suggest that Pnpla3 may influence NEFA and/or cholesterol homeostasis under specific nutritional/metabolic conditions.
Since Pnpla3 is positively regulated by the lipogenic nuclear transcription factor LXR (38), we additionally measured phenotypic parameters in a separate cohort of 12 week-old, 4h-fasted, chow-fed male mice that were treated with the potent LXR agonist T0901317 for 6 days.
This treatment regimen has previously been shown to induce hepatic Pnpla3 mRNA expression by 6 to 16-fold over the duration of the treatment (38), and would thereby be expected to enhance phenotypic differences between genotype groups. As expected, T0901317 treatment increased serum cholesterol and hepatic TAG content to levels comparable to its previously reported effects under similar experimental conditions (50) 
Global deletion of Pnpla3 does not contribute to hepatic steatosis or injury.
Recently, genetic variation in the human PNPLA3 gene has been strongly and repeatedly associated with fatty liver disease in humans. We, therefore, assessed the effect of Pnpla3 deficiency on hepatic lipid content and injury (Fig. 6) . Although the expected increases in hepatic TAG content were observed for LFHS and HFHS diet groups, no differences between genotypes were identified for liver weights (data not shown) or liver TAG content between genotypes for any of the diet groups, whether measured biochemically (Fig. 6A) or histologically by Oil Red O staining (data not shown). Since transacylase activity of PNPLA3 could result in physiologically significant changes in TAG molecular species without a net overall change in TAG mass, we further characterized TAG molecular species using electrospray ionization tandem mass spectrometry (59, 60). However, individual TAG molecular species also did not differ between genotypes for liver ( Fig. 6B) or WAT (data not shown). Serum AST (Fig. 6C) and ALT ( Fig. 6D) , markers of hepatic injury, also did not differ between genotypes. Given the above interactive effects on serum NEFA and cholesterol, we additionally evaluated in vivo cholesterol and fatty acid metabolism in a separate cohort of 8-9 week old chow-fed mice using tritiated water. However, no differences in hepatic incorporation of [3H]-H 2 O into digitonin precipitable sterols (i.e. cholesterol) (Fig. 6E) or NEFAs (Fig. 6F) were identified. Similar results were obtained for NEFA biosynthesis in WAT and BAT (Fig. 6F) . These data suggest that Pnpla3 deficiency does not contribute to hepatic lipid metabolism, steatosis, or injury.
Global deletion of Pnpla3 promotes compensatory regulation of Pnpla5 mRNA but not
other genes/proteins involved in TAG metabolism.
To identify genes and/or pathways that might be compensating for Pnpla3 deficiency, we evaluated mRNA expression of genes involved in TAG metabolism in liver and perigonadal WAT of ad lib-fed WT and Pnpla3-KO mice fed chow, LFLS, LFHS, or HFHS diet from weaning until 19 weeks of age ( Fig. 7 and Supplemental Table 1 ). As expected, both diet and genotype had significant main effects on Pnpla3 mRNA expression in both WAT (Fig. 7A) and liver (Fig.   7B ). The diet-induced effect was particularly dramatic in liver where Pnpla3 mRNA was induced over 100-fold in LFHS-fed mice. It is worth noting that the LFLS diet (61% starch, 12% maltodextrin) also induced hepatic Pnpla3 mRNA expression by 29-fold compared to chow (60% starch) and 2-fold compared to HFHS-diet (25% sucrose), suggesting a positive regulatory effect of the more palatable/digestible maltodextrin carbohydrate component in the former and/or a suppressive regulatory effect of dietary fat in the latter. As expected, significant main effects of diet on mRNA expression of numerous genes involved in TAG metabolism were identified in both liver and WAT (Supplemental Table 1 ). However, no main effects of genotype on mRNA expression of these genes were identified for either tissue. In contrast, Pnpla5, a
Pnpla3 paralog with unclear function, was significantly increased in WAT of KO compared with WT mice (Fig. 7C) . Pnpla5 mRNA expression in liver was extremely low and could not be increase Pnpla3 expression and enhance differences between genotypes (i.e. re-feeding, high sucrose diet, diet-induced obesity, and pharmacological activation by LXR), likewise fail to reveal any differences in the above metabolic phenotypes. It is worth noting that, while this manuscript was in preparation, another group published similar data in an independentlygenerated model of global Pnpla3 deletion and additionally failed to identify any metabolic consequences of Pnpla3 deficiency in mice challenged with a methacholine-deficient diet or with leptin deficiency (66) . Together these data argue against a role for Pnpla3 loss-of-function in NAFLD and the metabolic syndrome, at least in mice.
Although genotype had no main effects on phenotype overall, two noteworthy interactions were identified in our study: 1) serum NEFAs were lower in LFHS-fed Pnpla3-KO mice (but tended to be higher in HFHS-fed mice); and 2) serum cholesterol was higher in re-fed variants and cholesterol/lipoprotein concentrations (10, 22, 23). Furthermore, in the present study, we were not able to identify differences between genotypes for NEFA or cholesterol metabolism using in vivo tritiated water methods. The lack of consistency of these findings across outcomes stresses the need for further exploration of these results. Finally, it is also worth noting that hepatic TG content, though not statistically different, was consistently slightly higher in Pnpla3-KO mice in our studies (Fig. 6A, 6B , and unpublished data). Thus, it is possible that alternative metabolic conditions, enhanced statistical power, and/or a more homogeneous background strain could unmask previously unrecognized phenotypes in Pnpla3-KO mice. Nevertheless, numerous studies have demonstrated a strong association between genetic variation in PNPLA3 and hepatic steatosis, hepatic injury, and progression of NAFLD (10-24).
The human rs738409 variant is of particular interest because it contains a C→G nucleotide change that encodes for a methionine in place of isoleucine at position 148 (I148M mutation).
Computer modeling suggests that this mutation might alter substrate access to the putative catalytic serine residue in the conserved GXSXG motif (44) . Indeed, both the human I148M mutant as well as a mutant in which the catalytic serine has been replaced by an alanine (S47A) lack in vitro TAG hydrolase activity (28, 44) , suggesting that the I148M allele contributes to species-specific differences exist in function, expression, and/or regulation of PNPLA3. Indeed, human and rodent PNPLA3 differ considerably at their C-termini and exhibit different expression patterns (i.e. human PNPLA3 mRNA is more highly expressed in liver) (38). However, the impact of these differences on function and physiology remains to be determined.
In summary, our data provide strong evidence against a critical role for PNPLA3 in murine TAG hydrolysis and also provide further important corroborative evidence against a role for 
